Hikal Ltd

- Hikal Limited does not plan any fresh equity fundraising as per the latest call. - For the current year, the company plans a CAPEX of approximately ₹200 crore. - The funding for this CAPEX is expected to be 50% from internal accruals and 50% through borrowings (debt). - The company already has outstanding term loans of ₹550 crore and working capital borrowings of ₹240 crore. - Debt repayments have already commenced and will continue over the next few years. - Kuldeep Jain (CFO) stated they are comfortable with current debt levels. - Long-term total debt levels are expected to remain roughly stable by March 2024. - Cost of funds for the long-term borrowings is approximately 8.5%.

- Current capital work-in-progress (WIP) as of June 30, 2023 is about ₹400-460 crores, largely for recently completed projects. - Additional CAPEX of ₹100-120 crores is expected over the next three quarters to fully commission new capacities. - New multipurpose animal health plant at Panoli is built and undergoing commissioning with validation batches expected in the next few quarters. - The new capacity ramp-up will add around ₹500-600 crores in revenue potential beyond the existing asset base. - Company plans about ₹200 crore investment in the current year, funded roughly 50% by internal accruals and 50% by debt. - Debt for CAPEX is manageable; no new long-term loans borrowed in recent quarter; debt-equity ratio is well within norms. - Commissioning and revenue contribution from new assets expected mainly from Q3/Q4 FY24 onwards. - Strategic focus on enhancing manufacturing, supply chain, and ESG integration through "Project Pinnacle" for sustainable growth.

- Revenue target of around ₹3,000 crore expected in a few years; not within the next two years but slightly beyond that (Sameer Hiremath). - Existing gross block can achieve ₹2,400-2,500 crore with improved utilization and better product mix; new capacity to add ₹500-600 crore (Sameer Hiremath). - Volumes declined in Q1 FY24 due to inventory destocking; volume uptick expected from Q3 FY24 onwards (Sameer Hiremath). - Peak utilization of new capacity will take 3-4 years to achieve (Sameer Hiremath). - Topline of ₹3,500 crore expected once optimal capacities are reached, which is 2-3 years post commissioning (Sameer Hiremath). - Improvement expected in volumes and margins from H2 FY24 onwards; sequential quarter-on-quarter recovery anticipated (Sameer Hiremath). - Medium to long-term growth outlook positive; demand recovery expected in pharma and crop protection segments (Sameer Hiremath, Manoj Mehrotra).

- Hikal expects a medium to long-term sustainable growth outlook despite short-term volatility, with demand uptick anticipated from Q3/Q4 FY24 onwards. - Operating margins are targeted to improve from current 13%-14% levels back to historical 18%-19% within a few years for existing assets; new projects aim for EBITDA margins around 22%-24%. - The company’s aspirational revenue target is around Rs. 3,000 crore in a few years, with current assets contributing Rs. 2,400-2,500 crore and new capacity adding Rs. 500-600 crore. - Longer-term targets are significantly higher, with confidence in exceeding revenue of Rs. 6,000 crore by 2030; failure to do so would cause disappointment. - EBITDA margins for the new projects target approximately 24%-25%, with a blended margin expected around 20%-23%. - Enhanced operational efficiencies, new product mix, and commissioned capacities underpin growth and margin improvements over the next 3-5 years.

- The transcript does not provide specific details or figures regarding the current or expected order book or pending orders for Hikal Limited. - However, the company mentions a strong pipeline of products under evaluation and implementation for global multinational clients. - There is also mention of onboarding several new customers due to increased marketing efforts. - The company highlights ongoing positive discussions with global innovators and opportunities for setting up dedicated capacities for clients. - Overall, while exact order book numbers are not disclosed, the company indicates healthy demand prospects, ongoing client engagements, and a favorable outlook for order inflow.